Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 276

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Clinical trial links oncolytic immunoactivation to survival in glioblastoma

Open access
Ling, Alexander L., Solomon, Isaac H., Landivar, Ana Montalvo, Nakashima, Hiroshi, Woods, Jared K., Santos, Andres, Masud, Nafisa, Fell, Geoffrey, Mo, Xiaokui, Yilmaz, Ayse S., Grant, James, Zhang, Abigail, Bernstock, Joshua D., Torio, Erickson, Ito, Hirotaka, Liu, Junfeng, Shono, Naoyuki, Nowicki, Michal O., Triggs, Daniel, Halloran, Patrick, Piranlioglu, Raziye, Soni, Himanshu, Stopa, Brittany, Bi, Wenya Linda, Peruzzi, Pierpaolo, Chen, Ethan, Malinowski, Seth W., Prabhu, Michael C., Zeng, Yu, Carlisle, Anne, Rodig, Scott J., Wen, Patrick Y., Lee, Eudocia Quant, Nayak, Lakshmi, Chukwueke, Ugonma, Gonzalez Castro, L. Nicolas, Dumont, Sydney D., Batchelor, Tracy, Kittelberger, Kara, Tikhonova, Ekaterina, Miheecheva, Natalia, Tabakov, Dmitry, Shin, Nara, Gorbacheva, Alisa, Shumskiy, Artemy, Frenkel, Felix, Aguilar-Cordova, Estuardo, Aguilar, Laura K., Krisky, David, Wechuck, James, Manzanera, Andrea, Matheny, Chris, Tak, Paul P., Barone, Francesca, Kovarsky, Daniel, Tirosh, Itay, Suvà, Mario L., Wucherpfennig, Kai W., Ligon, Keith, Reardon, David A., Chiocca, E. Antonio·2023·Nature

Abstract

Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM)1,2. Here we report the results of a first-in-human phase I trial in 41 patients with rGBM who were injected with CAN-3110—an oncolytic herpes virus (oHSV)3. In contrast to other clinical oHSVs, CAN-3110 retains the viral neurovirulence ICP34.5 gene transcribed by a nestin promoter; nestin is overexpressed in GBM and other invasive tumours, but not in the adult brain or healthy differentiated tissue 4. These modifications confer CAN-3110 with preferential tumour replication. No dose-limiting toxicities were encountered. Positive HSV1 serology was significantly associated with both improved survival and clearance of CAN-3110 from injected tumours. Survival after treatment, particularly in individuals seropositive for HSV1, was significantly associated with (1) changes in tumour/PBMC T cell counts and clonal diversity, (2) peripheral expansion/contraction of specific T cell clonotypes; and (3) tumour transcriptomic signatures of immune activation. These results provide human validation that intralesional oHSV treatment enhances anticancer immune responses even in immunosuppressive tumour microenvironments, particularly in individuals with cognate serology to the injected virus. This provides a biological rationale for use of this oncolytic modality in cancers that are otherwise unresponsive to immunotherapy (ClinicalTrials.gov: NCT03152318).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-023-06623-2

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Cited by

See all 276

Metadata

Authors
Ling, A. L., Solomon, I. H., Landivar, A. M., Nakashima, H., Woods, J. K., Santos, A., Masud, N., Fell, G., Mo, X., Yilmaz, A. S., Grant, J., Zhang, A., Bernstock, J. D., Torio, E., Ito, H., Liu, J., Shono, N., Nowicki, M. O., Triggs, D., Halloran, P., Piranlioglu, R., Soni, H., Stopa, B., Bi, W. L., Peruzzi, P., Chen, E., Malinowski, S. W., Prabhu, M. C., Zeng, Y., Carlisle, A., Rodig, S. J., Wen, P. Y., Lee, E. Q., Nayak, L., Chukwueke, U., Gonzalez Castro, L. N., Dumont, S. D., Batchelor, T., Kittelberger, K., Tikhonova, E., Miheecheva, N., Tabakov, D., Shin, N., Gorbacheva, A., Shumskiy, A., Frenkel, F., Aguilar-Cordova, E., Aguilar, L. K., Krisky, D., Wechuck, J., Manzanera, A., Matheny, C., Tak, P. P., Barone, F., Kovarsky, D., Tirosh, I., Suvà, M. L., Wucherpfennig, K. W., Ligon, K., Reardon, D. A., & Chiocca, E. A.
Venue
Nature
Published
2023-10-18
Volume
623
Issue
7985
Pages
157-166
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4387744072
Cited by
276
References
44
FWCI
40.43
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical trial links oncolytic immunoactivation to survival in glioblastoma. https://app.cochat.ai/papers/10.1038/s41586-023-06623-2
The paper
Ling, A. L., Solomon, I. H., Landivar, A. M., Nakashima, H., Woods, J. K., Santos, A., Masud, N., Fell, G., Mo, X., Yilmaz, A. S., Grant, J., Zhang, A., Bernstock, J. D., Torio, E., Ito, H., Liu, J., Shono, N., Nowicki, M. O., Triggs, D., . . . Chiocca, E. A. (2023). Clinical trial links oncolytic immunoactivation to survival in glioblastoma. Nature. https://doi.org/10.1038/s41586-023-06623-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.